Stockscreener 앱 받기
15.71
6.73%
0.99
시간 외 거래:
15.71
전일 마감가:
$14.72
열려 있는:
$14.92
하루 거래량:
1.32M
Relative Volume:
0.81
시가총액:
$1.26B
수익:
$123.67M
순이익/손실:
$-38.63M
주가수익비율:
-25.46
EPS:
-0.617
순현금흐름:
$-27.50M
1주 성능:
-0.32%
1개월 성능:
-13.16%
6개월 성능:
+139.85%
1년 성능:
+177.07%
1일 변동 폭
$14.88
$16.04
1주일 범위
$14.20
$16.45
52주 변동 폭
$3.5001
$25.77
Monte Rosa Therapeutics Inc Stock (GLUE) Company Profile
명칭
Monte Rosa Therapeutics Inc
전화
617-949-2643
주소
321 HARRISON AVENUE, BOSTON
Compare GLUE vs VRTX, REGN, ALNY, ARGX, INSM
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GLUE
Monte Rosa Therapeutics Inc
|
15.71 | 1.18B | 123.67M | -38.63M | -27.50M | -0.617 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Monte Rosa Therapeutics Inc Stock (GLUE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-19 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-02-15 | 개시 | Wedbush | Outperform |
| 2023-01-03 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2022-10-13 | 개시 | UBS | Buy |
| 2022-08-15 | 개시 | Jefferies | Buy |
| 2022-04-28 | 개시 | Credit Suisse | Neutral |
| 2022-02-10 | 개시 | Wells Fargo | Equal Weight |
| 2021-10-14 | 개시 | SVB Leerink | Mkt Perform |
모두보기
Monte Rosa Therapeutics Inc 주식(GLUE)의 최신 뉴스
Analysts Are Bullish on Top Healthcare Stocks: Perspective Therapeutics (CATX), Gain Therapeutics (GANX) - The Globe and Mail
Aug Ideas: Can Monte Rosa Therapeutics Inc lead its sector in growthQuarterly Trade Review & Smart Investment Allocation Tips - baoquankhu1.vn
Can Monte Rosa Therapeutics Inc lead its sector in growthTrade Ideas & Long-Term Capital Growth Ideas - baoquankhu1.vn
Breakouts Watch: How sensitive is Monte Rosa Therapeutics Inc to inflationQuarterly Market Review & Growth Focused Stock Reports - baoquankhu1.vn
Big Picture: Does Monte Rosa Therapeutics Inc stock have upside surprise potentialRate Hike & Weekly Breakout Opportunity Watchlist - baoquankhu1.vn
Wall Street Zen Downgrades Monte Rosa Therapeutics to 'Sell' - National Today
Monte Rosa Therapeutics (NASDAQ:GLUE) Downgraded by Wall Street Zen to "Sell" - MarketBeat
Risks Report: Is Monte Rosa Therapeutics Inc forming a bullish divergenceQuarterly Earnings Summary & Verified Technical Signals - baoquankhu1.vn
Does Monte Rosa Therapeutics Inc stock have upside surprise potential - baoquankhu1.vn
NEA group (NASDAQ: GLUE) discloses 9.6% Monte Rosa ownership - Stock Titan
Wells Fargo Sticks to Its Buy Rating for Monte Rosa Therapeutics (GLUE) - The Globe and Mail
Analysts Are Bullish on Top Healthcare Stocks: Lantheus (LNTH), Perspective Therapeutics (CATX) - The Globe and Mail
Monte Rosa Therapeutics (NASDAQ:GLUE) Announces Earnings Results, Misses Estimates By $0.10 EPS - MarketBeat
Guggenheim Lowers Monte Rosa Therapeutics (NASDAQ:GLUE) Price Target to $30.00 - MarketBeat
Monte Rosa Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Monte Rosa Therapeutics price target lowered to $30 from $34 at Guggenheim - TipRanks
Monte Rosa Therapeutics (GLUE) Quarterly Loss Tests Bullish Profitability Narrative - simplywall.st
Monte Rosa (GLUE) Reports Wider Q4 Loss of $0.55/Share vs $0.34 Estimate, Revenue Misses - AlphaStreet
Analysts Are Bullish on Top Healthcare Stocks: Alto Neuroscience, Inc. (ANRO), Monte Rosa Therapeutics (GLUE) - The Globe and Mail
Monte Rosa Therapeutics Reports Positive Clinical Data and $345M Financing, Advancing Multiple Phase 2 Trials into 2029 - Minichart
Is Monte Rosa Therapeutics Inc stock a hidden gem2026 Earnings Surprises & Advanced Technical Signal Analysis - baoquankhu1.vn
Monte Rosa Therapeutics (GLUE) reports Q4 loss, misses revenue estimates - MSN
Monte Rosa Therapeutics, Inc. (GLUE) Reports Wider Loss Q4 EPS Estimates by 63.4% - AlphaStreet
Monte Rosa’s QuEEN™ Discovery Engine: AI-Driven Molecular Glue Degraders Targeting Undruggable Proteins in Biotechnology 4145465158 - Minichart
Monte Rosa Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Monte Rosa Therapeutics: Fourth Quarter Financial Results Overview - Bitget
Monte Rosa Therapeutics, Inc. Announces Executive Changes - marketscreener.com
Monte Rosa Therapeutics (GLUE) 2025 Financials: Q4 Loss, Revenue MissNews and Statistics - IndexBox
Monte Rosa Therapeutics touts molecular glue pipeline, tees up GFORCE updates and Phase II plans - MarketBeat
Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates - Investing News Network
Monte Rosa Therapeutics (GLUE) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
Monte Rosa Therapeutics Swings to Net Loss in Q4, Collaboration Revenue Falls - marketscreener.com
Monte Rosa Therapeutics: Q4 Earnings Snapshot - Barchart.com
Monte Rosa Therapeutics : Corporate Presentation – March 2026 - marketscreener.com
Monte Rosa Therapeutics (NASDAQ: GLUE) touts MGD pipeline and major Novartis, Roche deals - Stock Titan
Monte Rosa Therapeutics Q4 revenue drops, net loss widens on lower milestone payments - TradingView
Earnings Flash (GLUE) Monte Rosa Therapeutics, Inc. Reports Q4 Revenue $2.8M - marketscreener.com
Monte Rosa Therapeutics (GLUE) extends cash runway to 2029 after $345M raise - Stock Titan
Heart risk, prostate cancer: Monte Rosa data and $345M war chest - Stock Titan
Does Monte Rosa (GLUE)–J&J ERLEADA Supply Deal Reframe GLUE’s MYC Degrader Investment Story? - simplywall.st
GLUE SEC FilingsMonte Rosa Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Monte Rosa rises on J&J collaboration for cancer therapy trial (GLUE:NASDAQ) - Seeking Alpha
Monte Rosa Therapeutics Announces Clinical Supply Agreement to Support Phase 2 Trial Evaluating MRT-2359 in Combination with Apalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer - Bitget
GLUE Stock Price, Quote & Chart | MONTE ROSA THERAPEUTICS INC (NASDAQ:GLUE) - ChartMill
Monte Rosa Therapeutics (GLUE) Reports Q2 Loss, Tops Revenue Estimates - MSN
Monte Rosa Therapeutics (GLUE) Likely to Surpass Earnings Forecasts: Will the Share Price Rise? - Bitget
Monte Rosa Therapeutics (GLUE) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Yahoo Finance
Monte Rosa Therapeutics (GLUE) to Release Quarterly Earnings on Thursday - MarketBeat
Monte Rosa Therapeutics earnings on deck amid revenue decline By Investing.com - Investing.com Australia
Monte Rosa Therapeutics earnings on deck amid revenue decline - Investing.com
Assessing Monte Rosa Therapeutics (GLUE) Valuation After MRT-2359 Data Update And New Public Offering - Yahoo Finance
Monte Rosa Therapeutics Inc (GLUE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.82%
자본화:
|
볼륨(24시간):